Trials / Completed
CompletedNCT01321957
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.
Detailed description
5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) in combination with bevacizumab is regarded as standard first-line treatment in metastatic colorectal cancer \[Saltz et al., 2008\]. Current studies established the role of the FOLFOXIRI regimen \[Souglakos et al., 2006, Falcone et al., 2007\]. A further intensification of the therapy seems feasible yielding response rates up to 84% and a disease control rate up to 100% \[Falcone, 2008, Santomaggio, 2009, Masi, 2010\]. This trial evaluates the activity of an intensified first-line therapy for metastatic colorectal cancer compared to standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin, 5FU/LV, Bevacizumab | bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3) |
| DRUG | 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan | bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3) |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2016-09-01
- Completion
- 2018-08-15
- First posted
- 2011-03-24
- Last updated
- 2018-10-25
Locations
51 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01321957. Inclusion in this directory is not an endorsement.